Cisplatin	0	9	B-Drug_or_compound
reduces	10	17	O
endothelial	18	29	B-Cell
cell	30	34	I-Cell
migration	35	44	O
via	45	48	O
regulation	49	59	O
of	60	62	O
type	63	67	B-Gene_or_gene_product
2	68	69	I-Gene_or_gene_product
-	69	70	I-Gene_or_gene_product
matrix	70	76	I-Gene_or_gene_product
metalloproteinase	77	94	I-Gene_or_gene_product
activity	95	103	O
.	103	104	O

AIMS	106	110	O
:	110	111	O
In	112	114	O
this	115	119	O
study	120	125	O
we	126	128	O
investigated	129	141	O
the	142	145	O
effect	146	152	O
of	153	155	O
cisplatin	156	165	B-Drug_or_compound
on	166	168	O
endothelial	169	180	B-Cell
cell	181	185	I-Cell
migration	186	195	O
,	195	196	O
an	197	199	O
essential	200	209	O
process	210	217	O
for	218	221	O
vascular	222	230	B-Multi-tissue_structure
remodeling	231	241	O
and	242	245	O
regeneration	246	258	O
in	259	261	O
several	262	269	O
physiological	270	283	O
and	284	287	O
pathological	288	300	O
situations	301	311	O
.	311	312	O

MATERIAL	313	321	O
AND	322	325	O
METHODS	326	333	O
:	333	334	O
Human	335	340	B-Cell
umbilical	341	350	I-Cell
vein	351	355	I-Cell
endothelial	356	367	I-Cell
cells	368	373	I-Cell
(	374	375	O
HUVEC	375	380	B-Cell
)	380	381	O
were	382	386	O
treated	387	394	O
with	395	399	O
cisplatin	400	409	B-Drug_or_compound
and	410	413	O
endothelial	414	425	B-Cell
cell	426	430	I-Cell
migration	431	440	O
analyzed	441	449	O
by	450	452	O
fluorescence	453	465	O
and	466	469	O
scratch	470	477	O
-	477	478	O
wound	478	483	O
migration	484	493	O
assay	494	499	O
.	499	500	O

MMP2	501	505	B-Gene_or_gene_product
and	506	509	O
MMP9	510	514	B-Gene_or_gene_product
activity	515	523	O
were	524	528	O
determined	529	539	O
by	540	542	O
zymographic	543	554	O
assay	555	560	O
,	560	561	O
and	562	565	O
MAPK	566	570	B-Gene_or_gene_product
activation	571	581	O
by	582	584	O
Western	585	592	O
blotting	593	601	O
analysis	602	610	O
.	610	611	O

RESULTS	612	619	O
:	619	620	O
We	621	623	O
demonstrated	624	636	O
that	637	641	O
cisplatin	642	651	B-Drug_or_compound
provoked	652	660	O
a	661	662	O
time	663	667	O
-	667	668	O
and	669	672	O
dose	673	677	O
-	677	678	O
dependent	678	687	O
decrease	688	696	O
of	697	699	O
HUVEC	700	705	B-Cell
migration	706	715	O
;	715	716	O
this	717	721	O
effect	722	728	O
was	729	732	O
clearly	733	740	O
independent	741	752	O
from	753	757	O
its	758	761	O
well	762	766	O
known	767	772	O
cytotoxic	773	782	O
activity	783	791	O
.	791	792	O

In	793	795	O
addition	796	804	O
,	804	805	O
cisplatin	806	815	B-Drug_or_compound
markedly	816	824	O
reduced	825	832	O
MMP2	833	837	B-Gene_or_gene_product
activity	838	846	O
in	847	849	O
both	850	854	O
conditioned	855	866	O
media	867	872	O
and	873	876	O
cell	877	881	B-Organism_substance
lysates	882	889	I-Organism_substance
,	889	890	O
increased	891	900	O
p38	901	904	B-Gene_or_gene_product
MAPK	905	909	I-Gene_or_gene_product
and	910	913	O
JNK	914	917	B-Gene_or_gene_product
phosphorylation	918	933	O
,	933	934	O
but	935	938	O
did	939	942	O
not	943	946	O
affect	947	953	O
ERK	954	957	B-Gene_or_gene_product
phosphorylation	958	973	O
.	973	974	O

Endothelial	975	986	B-Cell
cell	987	991	I-Cell
migration	992	1001	O
was	1002	1005	O
attenuated	1006	1016	O
by	1017	1019	O
treatment	1020	1029	O
of	1030	1032	O
cells	1033	1038	B-Cell
with	1039	1043	O
GM6001	1044	1050	B-Drug_or_compound
,	1050	1051	O
a	1052	1053	O
non	1054	1057	O
-	1057	1058	O
specific	1058	1066	O
inhibitor	1067	1076	O
of	1077	1079	O
MMPs	1080	1084	B-Gene_or_gene_product
,	1084	1085	O
or	1086	1088	O
by	1089	1091	O
a	1092	1093	O
selective	1094	1103	O
anti	1104	1108	O
-	1108	1109	O
MMP2	1109	1113	B-Gene_or_gene_product
antibody	1114	1122	O
.	1122	1123	O

However	1124	1131	O
,	1131	1132	O
treatment	1133	1142	O
of	1143	1145	O
cells	1146	1151	O
with	1152	1156	O
SB202190	1157	1165	B-Drug_or_compound
or	1166	1168	O
SP600125	1169	1177	B-Drug_or_compound
,	1177	1178	O
inhibitors	1179	1189	O
of	1190	1192	O
p38	1193	1196	B-Gene_or_gene_product
MAPK	1197	1201	I-Gene_or_gene_product
and	1202	1205	O
JNK	1206	1209	B-Gene_or_gene_product
respectively	1210	1222	O
,	1222	1223	O
did	1224	1227	O
not	1228	1231	O
affect	1232	1238	O
HUVEC	1239	1244	B-Cell
migration	1245	1254	O
.	1254	1255	O

CONCLUSION	1256	1266	O
:	1266	1267	O
These	1268	1273	O
results	1274	1281	O
suggested	1282	1291	O
that	1292	1296	O
cisplatin	1297	1306	B-Drug_or_compound
induced	1307	1314	O
a	1315	1316	O
reduction	1317	1326	O
of	1327	1329	O
endothelial	1330	1341	B-Cell
cell	1342	1346	I-Cell
migration	1347	1356	O
through	1357	1364	O
an	1365	1367	O
inhibition	1368	1378	O
of	1379	1381	O
MMP2	1382	1386	B-Gene_or_gene_product
activity	1387	1395	O
by	1396	1398	O
downstream	1399	1409	O
signal	1410	1416	O
transduction	1417	1429	O
pathways	1430	1438	O
independent	1439	1450	O
of	1451	1453	O
JNK	1454	1457	B-Gene_or_gene_product
and	1458	1461	O
p38	1462	1465	B-Gene_or_gene_product
MAPK	1466	1470	I-Gene_or_gene_product
activation	1471	1481	O
.	1481	1482	O

